There were no adverse events attributed on the treatment, which resulted in a 100 percent lessen in unbound N-terminal tau fragments in CSF. There were no outcomes on exploratory steps of ailment severity. To Jubao Duan with the College of Chicago, the authors provide compelling evidence. That ta